Skip to Main Content

Phoenix is no Kendall Square. Its biotech companies, ventures like OncoMyx Therapeutics and VisionGate, haven’t generated one-tenth the buzz of companies like Moderna or CRISPR Therapeutics.

But if congressional Democrats’ drug pricing reforms fail, the tiny biotechs that pepper the Grand Canyon State deserve an outsized bit of the credit.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment